Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Leading integrated radiotherapy systems maker Varian Medical Systems (VAR - Analyst Report) has inked a pact with privately-held Augmenix, under which, Varian will make a $15 million equity investment in the latter. The agreement also provides the California-based company with an option to acquire Augmenix, which makes hydrogels used in radiation therapy.

Hydrogels, which primarily consist of water and polyethylene glycol (“PEG”), are used to improve outcomes in radiation oncology. Augmenix’s flagship product, the SpaceOAR System, is geared for use in patients undergoing radiation treatment for prostate cancer. 

The aim of radiation therapy is to maximize dose delivery to a tumor while sparing the surrounding healthy tissues and organs. SpaceOAR has been designed to reduce injury to the rectum (as its wall borders the prostate) during the course of treatment.

During radiation therapy, SpaceOAR is injected between the prostate and rectum, which safely moves the rectum away from the prostate. This mitigates the amount of radiation to the rectum during treatment. Following the therapy, the hydrogel liquefies and is absorbed in the body.

The SpaceOAR System is approved for marketing in select European countries and Australia and is currently under clinical investigation in the U.S. The product registered its first commercial use in prostate cancer patients in August 2010. The minority stake in Augmenix is in tandem with Varian’s commitment to offer radiation oncologists with advanced technologies that lead to improved therapeutic outcomes.  

Varian is the world’s leading manufacturer of integrated radiotherapy systems for treating cancer and a premier supplier of X-ray tubes for diagnostic imaging applications. In the radiation oncology market, the company competes head-to-head with Accuray Incorporated (ARAY - Analyst Report).

Varian is poised to increase its market share in the radiation oncology market. The company is currently enjoying a healthy demand for its coveted RapidArc radiotherapy technology. However, uncertainties stemming from health care reform and a still-weak hospital capital spending environment provide headwinds. We currently have a Neutral recommendation on Varian.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
DIXIE GROUP DXYN 15.84 +7.90%
BOFL HOLDING BOFI 85.30 +4.97%
RAMBUS INC RMBS 12.31 +4.41%
VIPSHOP HOLD VIPS 148.73 +4.35%
NETFLIX INC NFLX 345.74 +4.32%